Direct Rx is recalling 88 bottles of Metformin HCL E/R (extended-release) 500 mg tablets, a prescription medication used to manage blood sugar in patients with type 2 diabetes. The recall was initiated because testing detected N-Nitrosodimethylamine (NDMA) at levels higher than the acceptable daily intake set by the manufacturer. NDMA is a substance that is classified as a probable human carcinogen. These affected bottles were distributed in Florida and packaged by Direct Rx in Dawsonville, Georgia.
The product contains the impurity NDMA at levels that exceed safety standards. Long-term exposure to NDMA above acceptable levels is linked to an increased risk of developing cancer.
Refund and medical guidance
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.